T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Accel Entertainment
ACEL
$897M
| $349K | ﹤0.01% |
30,528
+2,185
| +8% | +$23K |
|
2552
Asure Software
ASUR
$219M
| $349K | ﹤0.01% |
36,992
+3,536
| +11% | +$29.7K |
|
2553
Claros Mortgage Trust
CMTG
$182M
| $349K | ﹤0.01% |
114,025
-14,053
| -11% | -$45.9K |
|
2554
Atea Pharmaceuticals
AVIR
$423M
| $348K | ﹤0.01% |
97,320
-213
| -0.2% | -$677 |
|
2555
E.W. Scripps
SSP
$260M
| $348K | ﹤0.01% |
87,073
+5,995
| +7% | +$20.2K |
|
2556
ReposiTrak
TRAK
$151M
| $348K | ﹤0.01% |
28,094
+5,400
| +24% | +$76.7K |
|
2557
Hallador Energy
HNRG
$679M
| $347K | ﹤0.01% |
18,208
+1,746
| +11% | +$35.4K |
|
2558
Sturm, Ruger & Co
RGR
$677M
| $347K | ﹤0.01% |
10,625
+432
| +4% | +$16K |
|
2559
ThredUp
TDUP
$290M
| $347K | ﹤0.01% |
54,154
+4,495
| +9% | +$36.4K |
|
2560
Telos
TLS
$304M
| $347K | ﹤0.01% |
67,936
+3,715
| +6% | +$23.2K |
|
2561
Ezcorp Inc
EZPW
$1.89B
| $345K | ﹤0.01% |
17,751
| – | – |
|
2562
Bit Digital
BTBT
$617M
| $344K | ﹤0.01% |
181,524
+11,060
| +6% | +$32K |
|
2563
Akebia Therapeutics
AKBA
$243M
| $343K | ﹤0.01% |
212,680
+9,511
| +5% | +$19.9K |
|
2564
UWM Holdings
UWMC
$417M
| $343K | ﹤0.01% |
78,306
+10,855
| +16% | +$58.4K |
|
2565
Arhaus
ARHS
$1.36B
| $342K | ﹤0.01% |
30,453
+3,347
| +12% | +$34.8K |
|
2566
Digimarc Corp
DMRC
$115M
| $341K | ﹤0.01% |
51,869
+21,900
| +73% | +$186K |
|
2567
Citizens
CIA
$183M
| $340K | ﹤0.01% |
70,353
+4,420
| +7% | +$24.3K |
|
|
NUTX
2568
Nutex Health
NUTX
$1.44B
| $340K | ﹤0.01% |
+2,060
| New | +$273K |
|
2569
Navigator Holdings
NVGS
$1.41B
| $340K | ﹤0.01% |
19,585
+2,260
| +13% | +$37.8K |
|
2570
Southern Missouri Bancorp
SMBC
$789M
| $340K | ﹤0.01% |
5,739
+615
| +12% | +$34.1K |
|
|
AHL
2571
DELISTED
Aspen Insurance
AHL
| $340K | ﹤0.01% |
9,146
+885
| +11% | +$32.6K |
|
|
GES
2572
DELISTED
Guess Inc
GES
| $339K | ﹤0.01% |
20,223
| – | – |
|
|
RPC
2573
Ridgepost Capital
RPC
$812M
| $339K | ﹤0.01% |
34,501
+2,748
| +9% | +$27.9K |
|
2574
Richtech Robotics
RR
$365M
| $339K | ﹤0.01% |
104,690
+69,841
| +200% | +$309K |
|
2575
iShares Biotechnology ETF
IBB
$10.8B
| $338K | ﹤0.01% |
2,000
| – | – |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.